Limits...
Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient.

Ghosn M, Dagher A, El-Karak F - J Biomed Res (2014)

Bottom Line: We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy.The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value.The prostate-specific antigen doubling time was found to be a good response predictor in the patient.

View Article: PubMed Central - PubMed

Affiliation: Hematology-Oncology Department, Faculty of Medicine, Saint-Joseph University , Beirut , Lebanon .

ABSTRACT
We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.

No MeSH data available.


Related in: MedlinePlus

PSA levels and doubling time in a 68-year-old male with metastatic castration resistant prostate cancer. PSA: prostate-specific antigen.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4585438&req=5

f01: PSA levels and doubling time in a 68-year-old male with metastatic castration resistant prostate cancer. PSA: prostate-specific antigen.

Mentions: In September 2009, the patient relapsed with bone metastasis at the right acetabulum (PSA: 5.9 ng/mL). He received 10 sessions of radiation therapy and was started on monthly zoledronic acid. In March 2010, his PSA level increased to 7.5 ng/mL (Fig. 1) and radiologic evaluation showed a stable bone defect affecting the right side of L4 vertebral body, with a soft tissue mass exhibiting mild increased uptake, but there were no signs suggesting local recurrence in the prostatic bed. He received 4 cycles of docetaxel while continuing the LHRH inhibitor.


Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient.

Ghosn M, Dagher A, El-Karak F - J Biomed Res (2014)

PSA levels and doubling time in a 68-year-old male with metastatic castration resistant prostate cancer. PSA: prostate-specific antigen.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4585438&req=5

f01: PSA levels and doubling time in a 68-year-old male with metastatic castration resistant prostate cancer. PSA: prostate-specific antigen.
Mentions: In September 2009, the patient relapsed with bone metastasis at the right acetabulum (PSA: 5.9 ng/mL). He received 10 sessions of radiation therapy and was started on monthly zoledronic acid. In March 2010, his PSA level increased to 7.5 ng/mL (Fig. 1) and radiologic evaluation showed a stable bone defect affecting the right side of L4 vertebral body, with a soft tissue mass exhibiting mild increased uptake, but there were no signs suggesting local recurrence in the prostatic bed. He received 4 cycles of docetaxel while continuing the LHRH inhibitor.

Bottom Line: We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy.The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value.The prostate-specific antigen doubling time was found to be a good response predictor in the patient.

View Article: PubMed Central - PubMed

Affiliation: Hematology-Oncology Department, Faculty of Medicine, Saint-Joseph University , Beirut , Lebanon .

ABSTRACT
We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.

No MeSH data available.


Related in: MedlinePlus